Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PHIO | 8-K | bullish | 5/10 | Phio Pharmaceuticals announced a key development milestone for its lead siRNA candidate PH-762, submitting a meeting req | Sep 14, 2026 |
| CELU | 8-K | mixed | 5/10 | Celularity regained compliance with Nasdaq's minimum bid price (Rule 5550(a)(2)) and minimum market value of listed secu | Sep 14, 2026 |
| BNTX | 6-K | bullish | 7/10 | BioNTech and OncoC4 reported updated Phase 3 data for gotistobart in squamous NSCLC, showing median overall survival of | Sep 14, 2026 |
| ONCO | 425 | bearish | 6/10 | Onconetix announced a bridge financing facility of up to $5M to Realbotix, its acquisition target, with an initial $2.5M | Sep 14, 2026 |
| SMMT | 8-K | bullish | 7/10 | Summit Therapeutics announced via 8-K that its partner Akeso presented updated overall survival (OS) data from the Phase | Sep 14, 2026 |
| GSK | 6-K | bullish | 7/10 | GSK announced positive overall survival data from the ARTEMIS-008 Phase III trial of Ris-Rez (risvutatug rezetecan) in r | Sep 14, 2026 |
| CGEM | 8-K | bullish | 7/10 | Cullinan Therapeutics announced positive Phase 3 REZILIENT3 trial results for zipalertinib plus chemotherapy in first-li | Sep 14, 2026 |
| PBM | 6-K | neutral | 4/10 | Psyence Biomedical formed Texas Ibogaine Research Corporation (TIRC), a Texas-based subsidiary to coordinate U.S. ibogai | Sep 14, 2026 |
| AZN | 6-K | bearish | 5/10 | AstraZeneca announced that the Phase III SERENA-4 trial of Etcamah (camizestrant) plus palbociclib in 1st-line advanced | Sep 14, 2026 |
| GSK | 6-K | bullish | 7/10 | GSK announced positive registrational data from the ARROS-1 trial evaluating Jideytro (zidesamtinib) in first-line ROS1- | Sep 14, 2026 |
| CRBP | 8-K | bullish | 7/10 | Corbus Pharmaceuticals announced positive topline data from its CANYON-1 Phase 1b trial of CRB-913, an oral CB1 inverse | Sep 14, 2026 |
| ARMP | 8-K | bullish | 7/10 | Armata Pharmaceuticals announced FDA Breakthrough Therapy designation for AP-SA02, its intravenous phage therapy for com | Sep 14, 2026 |
| IMCR | 8-K | bullish | 6/10 | Immunocore announced it has achieved target enrollment of 540 patients in its Phase 3 TEBE-AM registrational trial evalu | Sep 14, 2026 |
| QTTB | 8-K | neutral | 3/10 | Q32 Bio announced the appointment of Dr. José Trevejo as Chief Medical Officer and Dr. Ellie Hershberger as Chief Develo | Sep 14, 2026 |
| CANF | EFFECT | bearish | 6/10 | Can-Fite BioPharma received SEC effectiveness on two shelf registration statements (File Nos. 333-288890 and 333-269485) | Sep 14, 2026 |
| INDV | EFFECT | neutral | 4/10 | Indivior Pharmaceuticals' S-4 registration statement (File No. 333-298637) was declared effective by the SEC on Septembe | Sep 14, 2026 |
| NSRX | EFFECT | neutral | 3/10 | Nasus Pharma Ltd's shelf registration (F-3) on Form 333-298693 became effective on September 11, 2026, allowing the comp | Sep 14, 2026 |
| CLLS | 6-K | bearish | 6/10 | Cellectis announced a strategic transformation to become an in vivo gene editing company, advancing two preclinical prog | Sep 14, 2026 |
| NBTX | 6-K | bullish | 7/10 | Nanobiotix announced positive Phase 1 results for JNJ-1900 (NBTXR3) in inoperable, recurrent NSCLC, showing a 79% one-ye | Sep 14, 2026 |
| ETRA | S-1/A | neutral | 6/10 | Electra Therapeutics, a late clinical-stage biopharmaceutical company, filed Amendment No. 1 to its S-1 registration sta | Sep 14, 2026 |
| CMND | 6-K | neutral | 4/10 | Clearmind Medicine announced enrollment of the first two patients with Alcohol Use Disorder in its Phase 1/2 CMND-100 cl | Sep 14, 2026 |
| RADX | 6-K | bullish | 7/10 | Radiopharm Theranostics announced positive interim Phase 2b data for RAD101, a PET imaging agent for recurrent brain met | Sep 14, 2026 |
| LPCN | 8-K | bullish | 6/10 | Lipocine initiated the BLOOM Phase 3 study of LPCN 1154 (oral brexanolone) for postpartum depression, with first partici | Sep 14, 2026 |
| CATX | 8-K | bullish | 5/10 | Perspective Therapeutics announced a clinical collaboration and supply agreement with Merck to evaluate its targeted alp | Sep 14, 2026 |
| TAK | 6-K | bullish | 7/10 | Takeda announced FDA Priority Review acceptance of its NDA for zasocitinib (TAK-279) in moderate-to-severe plaque psoria | Sep 14, 2026 |
| RDY | 6-K | neutral | 3/10 | Dr. Reddy's disclosed that the USFDA completed a records assessment at its API manufacturing facility in Mexico (Jiutepe | Sep 14, 2026 |
| BCTXL | PRESS-RELEASE | neutral | 4/10 | BriaCell announced its seventh consecutive positive DSMB recommendation for the pivotal Phase 3 Bria-ABC study of Bria-I | Sep 14, 2026 |
| KTTA | PRESS-RELEASE | neutral | 4/10 | Pasithea Therapeutics announced it will present initial clinical data from its ongoing Phase 1/1b trial of PAS-004 in ad | Sep 14, 2026 |
| APGE | 15-12G | neutral | 4/10 | Apogee Therapeutics has filed a Form 15-12G to terminate its SEC registration and suspend reporting obligations, effecti | Sep 14, 2026 |
| TYRA | S-3ASR | neutral | 3/10 | Tyra Biosciences filed an automatic shelf registration statement (S-3ASR) on September 14, 2026, registering an unspecif | Sep 14, 2026 |